235 related articles for article (PubMed ID: 16340399)
1. Metabolic therapy for the diabetic patients with ischaemic heart disease.
Rosano GM; Vitale C; Volterrani M; Fini M
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S17-21. PubMed ID: 16340399
[TBL] [Abstract][Full Text] [Related]
2. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
Rosano GM; Vitale C; Fragasso G
Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
[TBL] [Abstract][Full Text] [Related]
3. Energy metabolism in the normal and in the diabetic heart.
Barsotti A; Giannoni A; Di Napoli P; Emdin M
Curr Pharm Des; 2009; 15(8):836-40. PubMed ID: 19275647
[TBL] [Abstract][Full Text] [Related]
4. Effects of metabolic approach in diabetic patients with coronary artery disease.
Fragasso G; Salerno A; Spoladore R; Cera M; Montanaro C; Margonato A
Curr Pharm Des; 2009; 15(8):857-62. PubMed ID: 19275650
[TBL] [Abstract][Full Text] [Related]
5. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
Stanley WC; Marzilli M
Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
[TBL] [Abstract][Full Text] [Related]
6. Optimization of cardiac metabolism in diabetes mellitus.
Vitale C; Collin P
Curr Pharm Des; 2008; 14(25):2537-50. PubMed ID: 18991671
[TBL] [Abstract][Full Text] [Related]
7. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
8. Rationale for a metabolic approach in diabetic coronary patients.
Stanley WC
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S11-5. PubMed ID: 16340398
[TBL] [Abstract][Full Text] [Related]
9. Meeting the challenge of chronic ischaemic heart disease with trimetazidine.
Marzilli M; Affinito S
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S23-7. PubMed ID: 16340400
[TBL] [Abstract][Full Text] [Related]
10. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
Marazzi G; Wajngarten M; Vitale C; Patrizi R; Pelliccia F; Gebara O; Pierri H; Ramires JA; Volterrani M; Fini M; Rosano GM
Int J Cardiol; 2007 Aug; 120(1):79-84. PubMed ID: 17134770
[TBL] [Abstract][Full Text] [Related]
11. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
12. Current Clinical Evidence of Trimetazidine in the Management of Heart Disease in Patients with Diabetes.
Mahajan S; Mahajan AU
J Assoc Physicians India; 2020 Nov; 68(11):46-50. PubMed ID: 33187037
[TBL] [Abstract][Full Text] [Related]
13. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
Stanley WC; Sabbah HN
Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
[No Abstract] [Full Text] [Related]
14. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
[TBL] [Abstract][Full Text] [Related]
15. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
16. [Role of trimetazidine in the treatment of diabetic microangiopathy in ischaemic heart disease].
Fi Z; Kovács G; Szentes V
Orv Hetil; 2015 May; 156(19):765-8. PubMed ID: 26039915
[TBL] [Abstract][Full Text] [Related]
17. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Lopaschuk GD
Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
[TBL] [Abstract][Full Text] [Related]
18. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
[TBL] [Abstract][Full Text] [Related]
19. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia.
El Banani H; Bernard M; Baetz D; Cabanes E; Cozzone P; Lucien A; Feuvray D
Cardiovasc Res; 2000 Sep; 47(4):688-96. PubMed ID: 10974217
[TBL] [Abstract][Full Text] [Related]
20. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
Wenmeng W; Qizhu T
Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
